Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic––pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

Author： Liederer Bianca M.   Berezhkovskiy Leonid M.   Dean Brian J.   Dinkel Vikki   Peng Jing   Merchant Mark   Plise Emile G.   Wong Harvey   Liu Xingrong  

Publisher： Informa Healthcare

ISSN： 1366-5928

Source： Xenobiotica, Vol.41, Iss.4, 2011-04, pp. : 327-339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor

By Wong H.   Chen J.Z.   Chou B.   Halladay J.S.   Kenny J.R.   La H.   Marsters J.C.   Plise E.   Rudewicz P.J.   Robarge K.   Shin Y.   Wong S.   Zhang C.   Khojasteh S.C.  

Xenobiotica, Vol. 39, Iss. 11, 2009-11 ,pp. : 850-861

Informa Healthcare

Access to resources Recommend Favorite

Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats

By Kim Juhyun   Wang Ronghua   Veverka Karen A.   Dalton James T.  

Xenobiotica, Vol. 43, Iss. 11, 2013-11 ,pp. : 993-1009

Informa Healthcare

Access to resources Recommend Favorite

CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro

By Eaglings V. A.   Wiltshire H.   Whitcombe I. W. A.   Back D. J.  

Xenobiotica, Vol. 32, Iss. 1, 2002-01 ,pp. : 1-17

Informa Healthcare

Access to resources Recommend Favorite

Synthesis, spectral analysis and in vitro microbiological evaluation of novel ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-enecarboxylates and 4,5-dihydro-6-(napthalen-2-yl)-4-aryl-2H-indazol-3-ols

By Kanagarajan V.   Thanusu J.   Gopalakrishnan M.  

Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 26, Iss. 1, 2011-02 ,pp. : 56-66

Informa Healthcare

Access to resources Recommend Favorite

Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians

By Kohlrausch Fabiana   Carracedo Ángel   Hutz Mara  

Molecular Biology Reports, Vol. 41, Iss. 3, 2014-03 ,pp. : 1453-1460

Springer Publishing Company

Access to resources Recommend Favorite